An understanding of cardio-oncology is critical for managing the cardiotoxic effects of cancer therapies through cardiovascular evaluation, monitoring, and potential cardioprotective treatments.
Answers are grounded in this paper and cite their sources.
Supports cardio-oncology integration in cancer care; extends prior reviews while leaving optimal protocols open for prospective trials.
An understanding of onco-cardiology or cardio-oncology is critical for the effective care of cancer patients. Virtually all antineoplastic agents are associated with cardiotoxicity, which can be divided into 5 categories: direct cytotoxic effects of chemotherapy and associated cardiac systolic dysfunction, cardiac ischemia, arrhythmias, pericarditis, and chemotherapy-induced repolarization abnormalities. Radiation therapy can also lead to coronary artery disease and fibrotic changes to the valves, pericardium, and myocardium. All patients being considered for chemotherapy, especially those who have prior cardiac history, should undergo detailed cardiovascular evaluation to optimize the treatment. Serial assessment of left ventricular systolic function and cardiac biomarkers might also be considered in selected patient populations. Cardiotoxic effects of chemotherapy might be decreased by the concurrent use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers. Antiplatelet or anticoagulation therapy might be considered in patients with a potential hypercoagulable state associated with chemotherapy or cancer. Open dialogue between both cardiologists and oncologists will be required for optimal patient care.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2010) conducted a review in Cancer and chemotherapy-induced cardiotoxicity. Antineoplastic agents and radiation therapy was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: